UnitedHealth Group stock faces Texas probe ahead of Q3 results

Published on 10/05/2026 at 19:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UnitedHealth Group stock faces a Texas investigation announced on October 5, 2026. Q2 revenue reached USD 112.03 billion before the October 13 results date.

Aquarell-Illustration abstrakter Gesundheits-App-Elemente in Türkis, Mint und Blau auf Papier — UnitedHealth Group US91324P1021 als abstraktes Aquarell mit Gesundheits-App-Icons in Blau und Grün, Illustration mit AI erstellt.

UnitedHealth Group (ISIN US91324P1021) was trading at USD 371.46 on the NYSE at 1:26 p.m. ET on October 5, 2026, while Texas Attorney General Ken Paxton announced an investigation into the insurer. The probe adds a regulatory issue to the companys countdown to third-quarter results.

Texas probe adds regulatory pressure

According to GuruFocus on October 5, 2026, the Texas investigation concerns allegations that UnitedHealth practices may have obstructed patients from receiving necessary care. The report says the attorney general issued Civil Investigative Demands as part of the inquiry.

For investors, the issue sits alongside a recovery story in the latest reported quarter. The regulatory process may place additional attention on UnitedHealths benefit-management practices while management prepares its next operating update.

Q2 figures set the earnings bar

UnitedHealth reported USD 112.03 billion in Q2 2026 revenue and adjusted EPS of USD 6.38, compared with consensus revenue of USD 110.81 billion and consensus EPS of USD 4.94, according to MarketBeat. The quarter therefore delivered a USD 1.44 adjusted EPS beat, while revenue exceeded consensus by USD 1.22 billion.

The same report states that UnitedHealth set fiscal 2026 adjusted EPS guidance at USD 19.50-20.00. That range gives the October results a clear benchmark, particularly after Q2 revenue growth of 0.4 percent from the prior-year quarter.

October 13 is the next checkpoint

UnitedHealth Group announced on September 15, 2026, that it will release Q3 2026 results before the market opens on October 13, 2026, followed by an 8:00 a.m. ET conference call. The date creates a near-term test for the USD 19.50-20.00 adjusted EPS framework.

MarketScreener lists a consensus Buy rating from 26 analysts and an average target of USD 481.72. Against the USD 371.46 intraday price, that target lies 29.7 percent above the price, making earnings execution and regulatory developments the two most visible variables in the setup.

UnitedHealth Group stock trades below its yearly high

UnitedHealth Group stock was trading at USD 371.46 on the NYSE at 1:26 p.m. ET on October 5, 2026, down 0.12 percent from the prior close of USD 371.90. The session range was USD 368.05 to USD 373.65, the 52-week range was USD 255.97 to USD 461.62, and market capitalization was USD 337.3 billion.